^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGF amplification

    i
    Other names: FGF, Fibroblast Growth Factor
    Related biomarkers:
    Mutation
    2ms
    FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib. (PubMed, Eur J Cancer)
    No abstract available
    Journal
    |
    FGF (Fibroblast Growth Factor)
    |
    FGF amplification
    |
    Balversa (erdafitinib)
    over1year
    Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer. (PubMed, Cancer J)
    Nonetheless, FGF/FGFR has been a promising target for HNSCC treatment, and recent preclinical studies demonstrate the potential of the combination treatment regimens involving FGFR inhibitors on HNSCC. Therefore, there are a number of FGFR inhibitors currently in clinical trials for the treatment of head and neck cancers.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    FGFR1 amplification • FGFR3 mutation • FGFR expression • FGFR3 amplification • FGF amplification
    over2years
    [VIRTUAL] FGF/FGFR Molecular Landscape in Breast Cancer (AMP 2021)
    Tumors with FGFR alterations may be sensitive to the pan-FGFR inhibitor erdafitinib, an FDA-approved therapy for bladder cancer with FGFR2/FGFR3 alterations... The OS and PFS were lower in patients with FGF amplifications without co-existing FGFR alterations. Co-existing aberrations of FGF3, FGF4, FGF19, and CCND1 have been associated with increased median number of alterations in a tumor, affecting PFS adversely. Amplification of ZNF703 has been observed in luminal B breast tumors, a subtype associated with aggressive disease progression and poor patient outcomes.
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • FGF4 (Fibroblast growth factor 4)
    |
    HER-2 positive • HR positive • FGFR1 amplification • FGF amplification
    |
    FoundationOne® CDx
    |
    Balversa (erdafitinib)
    over3years
    Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. (PubMed, Clin Cancer Res)
    Histologic transformation and other off-target molecular alterations are frequent early emerging resistance mechanisms to osimertinib and are associated with poor clinical outcomes.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • FGF (Fibroblast Growth Factor)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • MET amplification • RET fusion • RET mutation • MET mutation • BRAF fusion • EGFR mutation + PIK3CA mutation • EGFR G724S • BRAF amplification • FGF amplification
    |
    Tagrisso (osimertinib)
    over3years
    Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients. (PubMed, J Cancer)
    The microsatellite instability status was negatively associated with amplifications (p=0.0017). FGF/FGFR alterations were widely occurred in cancer patients, and the mutational landscape may contribute to the further study design and development of FGF/FGFR inhibitors.
    Clinical • Journal
    |
    MSI (Microsatellite instability) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR mutation • FGF amplification
    4years
    [VIRTUAL] Genomic landscape of FGF/FGFR pathway alternations across 12,372 pan-cancer patients. (ASCO 2020)
    Our study investigated the molecular landscape of FGF/FGFR pathway alternations and the interplay between co-occurrence and mutual exclusivity between pathway genes in a large pan-cancer cohort. FGF/FGFR pathway mutations occurs in a variety of solid tumors, indicating that these patients may benefit from FGFR inhibitors. Research Funding: None
    Clinical • Pan tumor
    |
    MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FGF (Fibroblast Growth Factor)
    |
    FGFR2 fusion • FGFR mutation • FGFR1 fusion • FGF amplification